In collaboration with DT Consulting, Carenity*, part of EvidentIQ, conducted a survey of patients whose primary condition was ankylosing spondylitis, bipolar disorder, breast cancer, chronic obstructive pulmonary disease, depression, diabetes, multiple sclerosis, Parkinson’s disease, or rheumatoid arthritis,  to see if pharma channels are performing well enough for patients.

As patients seek to become more informed and involved in their own healthcare, their health outcomes are closely tied to the pharmaceutical industry’s ability to engage with them. To assess the current state of this relationship, we surveyed patients in Europe and the U.S. so that our partner DT Consulting could put patients in the role of customer and applied our Customer Experience Quotient® (CXQ®) metric to see which CX efforts satisfied or disappointed patients.

In particular, we asked the patient:

What did you do when you last engaged with pharma-created services or information?

How do you most prefer to interact with pharmaceutical firms, and what kind of interaction do you actually have most often?

What was the most recent pharma-created service or information you used?

After your last engagement with pharma-created services or information, what did you do?

How did your most recent interaction with a pharmaceutical company affect your view of the following?

Has COVID-19 made you more or less likely to engage with pharma in the future?

Access the complete report

*What is Carenity?

Carenity by EvidentIQ is our leading social platform supporting +500,000 patients and caregivers worldwide, across +1,200 chronic and rare diseases. Carenity provides direct, timely and compliant access to patient real-world data. Our Carenity platforms help fulfill our unique offer for Real-World Evidence, Clinical Trial Optimization, as well as Scientific Communication and Publications.

Carenity connects people suffering from the same conditions by providing them with a free social network: friends, newsfeed, discussion forums, private messaging, etc. We are convinced that new technologies help members feel less alone and better informed.

Find out more.

In collaboration with DT Consulting, Carenity*, part of EvidentIQ, conducted a survey of patients from France, Germany, Italy, Spain, the UK, and the US to learn more about their experience with clinical trials.

Understanding the difference between participants’ expectations and their actual experiences is a key issue in advancing medical research.

What are patients’ expectations in terms of communication from the organization managing the clinical trial during a clinical trial?
How is the patient informed about the trial? And by which health actor first?
What channels of communication does the patient use most with the organization managing the clinical trial?
What factors have the most impact on a patient’s decision to complete a clinical trial?

Access the complete report

*What is Carenity?

Carenity by EvidentIQ is our leading social platform supporting +500,000 patients and caregivers worldwide, across +1,200 chronic and rare diseases. Carenity provides direct, timely and compliant access to patient real-world data. Our Carenity platforms help fulfill our unique offer for Real-World Evidence, Clinical Trial Optimization, as well as Scientific Communication and Publications.

Carenity connects people suffering from the same conditions by providing them with a free social network: friends, newsfeed, discussion forums, private messaging, etc. We are convinced that new technologies help members feel less alone and better informed.

Find out more.